(Adnkronos) - Si è recentemente concluso a Bologna, l’evento dal titolo “AmaZyng! a New treatment option for R/R DLBCL”, promosso da Sobi, a cui hanno partecipato i più autorevoli ematologi e oncoematologi a livello nazionale ed internazionale. Il tema al centro del dibattito è un nuovo trattamento per il linfoma diffuso a grandi cellule B, loncastuximab tesirine, che è entrato nella pratica clinica in Italia a marzo di quest’anno, come trattamento per i pazienti adulti con linfoma diffuso a grandi cellule B e linfoma ad alto grado a cellule B, recidivanti o refrattari, dopo due o più linee di terapia sistemica.
Category
🗞
NewsTranscript
00:00It was recently concluded in Bologna at the Star Hotel Excelsior the event of the title
00:09Amazing, a new treatment option for RR-DL-BCL, promoted by SOBI, to which have participated
00:17the most authoritative hematologists and oncohematologists at the national and international level.
00:22The theme at the center of the debate is a new treatment for the lymph spread to large
00:27B-cells, LONCASTUXIMAB DESIRINE, which entered clinical practice in Italy in March
00:34of this year, as a treatment for adult patients with lymphoma spread to large B-cells and
00:40lymphoma at high degree to B-cells, recidive or refractory, after two or more lines of
00:46systemic therapy.
00:47This is a drug that has entered the therapeutic approach of patients
00:54with lymphoma spread to large B-cells, it is an anti-CD19 drug, a cytotoxic substance
01:02that goes directly to rest the antibody on the cell surface of the neoplastic cell
01:10lymphoma, because it presents the anti-CD19 and at that point there is a linker, like a
01:17trap that enters, penetrates, creates a hole in the cell wall of the neoplastic cell where
01:24the cytotoxic substance is discharged, so it is a truly direct action on the neoplastic cell.
01:32Lymphomas are malignant tumors of the blood that derive from an abnormal growth of the
01:37lymphocytes, the cells of the immune system that protect the body from infection and tumors.
01:43So diffused large B-cell lymphoma is the most common type of non-Hodgkin lymphomas.
01:51It is generally considered an aggressive lymphoma, which generally means that the lymphoma cells
01:57are fast growing, patients generally present with symptoms, if you treat, if you don't
02:07treat the disease, patients generally have poor outcomes. Diffused large B-cell lymphoma
02:14being the most common non-Hodgkin lymphoma in the United States, there are about 20 to
02:2025,000 cases of diffused large B-cell lymphoma every year. In Italy, there are about 4 to 5,000
02:29new cases of diffused large B-cell lymphoma.
02:59Therefore, new approvals are welcome, such as the latest one obtained in the third line for the Oncastuximab,
03:12which gives the opportunity to treat patients already heavily pre-treated, who have received more than two lines of treatment,
03:23old patients, because the vast majority of these patients are old, in any Italian hematology.
03:32Because the therapies approved in the third line, such as the B-specific and the SSKRT, if they have not been used in the second line,
03:40are not therapies easily accessible to all centers, because the KRT centers are limited.
03:48Those who are not KRT centers do not have the expertise or the organization to be able to use the B-specific.
03:56Well, Oncastuximab is an effective treatment that works very quickly when it works,
04:05and we see it already within two months, which is quite tolerable.
04:14Moreover, it is easily accessible, it does not require a recovery, and it is a time-finished therapy.